Macrolides for the treatment of Pseudomonas aeruginosa infections?
Macrolides for the treatment of Pseudomonas aeruginosa infections?
复制标题
DOI:
10.1093/jac/40.2.153
复制
发表时间:
1997-08-01
影响因子:
5.2
通讯作者:
Spencer, RC
中科院分区:
文献类型:
--
作者:
Howe, RA;Spencer, RC
In-vitro susceptibility testing is performed in order to predict the clinical efficacy of different antibiotics for a given infection. An organism is usually said to be sensitive to an antibiotic when the antibiotic concentration achieved at the site of infection is equal to, or exceeds, the MIC for that organism. Lorian & Burns1 showed in 1990 that patients treated with antibiotics to which the infecting organism was sensitive had a much better outcome than those treated with antibiotics to which the organism was resistant in vitro.The MIC of macrolides for most Pseudomonas aeruginosa strains is in the range 128–512 mg/L. Peak serum concentrations of erythromycin after a 250 mg oral dose are, however, only 1.0–1.5 mg/L and in one study the mean sputum concentration after an intravenous dose of 1 g every 12 h was 2.6 mg/L. 2 Thus, judged by conventional criteria, P. aeruginosa is resistant to the macrolides. However, there is increasing evidence of a role for macrolides in the treatment of certain pseudomonal infections. Interest in this area followed the observation in 1982 that patients suffering from diffuse panbronchiolitis (DPB) improved during long-term macrolide treatment. 3 DPB is a chronic lung disease, described almost exclusively in Japan, that is clinically and bacteriologically similar to cystic fibrosis. 4, 5 Initial infections with Haemophilus